Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,237
datasets available to search
ShareScore release 0.9.0
Dataset results
1,237 results for “treatment outcome”
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD
ClinicalTrials.gov study NCT04759703. IPD Sharing: YES. Countries: 1. Publications: 3.
Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
ClinicalTrials.gov study NCT04154631. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers
ClinicalTrials.gov study NCT00781599. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
ClinicalTrials.gov study NCT01599286. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthriti
ClinicalTrials.gov study NCT03928184. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Outcome of breast cancer in Moroccan young women correlated to clinic-pathological features, risk factors and treatment: a comparative study of 716 cases in a single institution
Background: Breast cancer in young women is quite uncommon and shows more aggressive characteristics with major disparities between worldwide populations. Prognosis and outcome of breast cancer in young patients are widely studied, but still no consensus is available. Methods: We retrospectively included 716 cases of breast cancer women diagnosed in 2009 at the National Institute of Oncology of Rabat. Patients were divided into two groups according to their age: women aged ≤40 years (Group 1) and women aged >40 years (Group 2). Data were recorded from patients' medical files and analyzed using SPSS 13.0 software (IBM). Results: Young patients represent 24.9% of all patients with breast cancer. The comparison between the two groups displayed significant differences regarding nulliparity (p = 0.001) and progesterone receptor negativity (p = 0.01). Moreover, more progression (Metastases/Relapse) was registered in young women as compared to older women with breast cancer (p = 0.03). The estimated median follow-up period was 31 months. The 5-years Event-Free Survival (EFS) of patients with local disease was 64.6% in young women and 71.5% in older women with breast cancer (p = 0.04). Multivariate analysis in young women showed that nulliparity (HR: 7.2; 95%CI: 1.16–44.54; p = 0.03), T3 tumors (HR: 17.39; 95%CI: 1.74–173.34; p = 0.01) and negative PgR status (HR: 19.85; 95%CI: 1.07–366.54; p = 0.04) can be considered as risk factors for poorer event free survival while hormone therapy was associated with better EFS (HR: 0.11; 95%CI: 0.00–0.75; p = 0.03). In Group 2, multivariate analysis showed that patients with inflammatory breast cancer, N+ status, absence of radiotherapy, absence of chemotherapy, and absence of hormone therapy are at increased risk of recurrence. Conclusions: In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. Moreover, the main factors associated with breast cancer development in young women would be hormonal and reproductive status. Analysis of other genetic biomarkers is needed to explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco
Data from: An investigation of sepsis surveillance and emergency treatment on patient mortality outcomes: an observational cohort study
Objective. To determine the prevalence of initiating the sepsis 3-hour bundle of care and estimate effects of bundle completion on risk-adjusted mortality among ED patients screened-in by electronic surveillance. Materials and Methods. This was a multiple center observational cohort study conducted in 2016. The study population was comprised of patients screened-in by St. John Sepsis Surveillance Agent within four hours of ED arrival, had a sepsis bundle initiated, and admitted to hospital. We built multivariable logistic regression models to estimate impact of a 3-hour bundle completed within three hours of arrival on mortality outcomes. Results. Approximately 3% ED patients were screened-in by electronic surveillance within four hours of arrival and admitted to hospital. Nearly 7 in 10 (69%) patients had a bundle initiated, with most bundles completed within three hours of arrival. The fully-adjusted risk model achieved good discrimination on mortality outcomes (AUROC = .82, 95% CI = .79 to .85) and estimated 34% reduced mortality risk among patients with a bundle completed within three hours of arrival compared to non-completers. Discussion. The sepsis bundle is an effective intervention for many vulnerable patients, and likely to be completed within three hours after arrival when electronic surveillance with reliable alert notifications are integrated into clinical workflow. Beginning at triage, the platform and sepsis program enables identification and management of patients with greater precision, and increases the odds of good outcomes. Conclusion. Sepsis surveillance and clinical decision support accelerate accurate recognition and stratification of patients, and facilitate timely delivery of healthcare.
Do we get better outcomes from early treatment of class III discrepancies?
<p>Dataset for performed meta-analyses.</p>
Supplemental files for Clinical outcome after endovascular treatment in patients with active cancer and ischemic stroke: a MR CLEAN Registry substudy
<p>Supplemental files for Clinical outcome after endovascular treatment in patients with active cancer and ischemic stroke: a MR CLEAN Registry substudy</p>
Comparison of Clinical Outcomes Between Liposuction and Liposuction in Combination with Microsurgery for Lymphedema Treatment: A Proportions Meta-Analysis
<p>Funnel plots for heterogenicity of each subgroup analysis. a) Excess Volume Reduction Lipo subgroup. b) Excess Volume Reduction Lipo+Micro subgroup. c) Decrease/reduction in post-operative use of compression garment subgroup Lipo. d) Decrease/reduction in post-operative use of compression garment subgroup Lipo+Micro. e) Post-operative reduction of erysipelas/cellulitis subgroup Lipo. f) Post-operative reduction of erysipelas/cellulitis subgroup Lipo+Micro.</p>
Evaluation of assisted reproductive technology treatment outcomes based on stimulation dosages and anti-mullerian hormone levels
<p><span>Background: </span><span>Serum concentrations of anti-mullerian hormone (AMH) correlate with ovarian response during assisted reproductive (ART) treatment cycles. This prospective study was attempted to evaluate the selection of ovarian stimulation protocols based on serum AMH levels in patients and its impact on the results of ART.</span></p> <p><span>Results</span></p> <p><span>According to the AMH levels, majority of the patients were normal responders (52.4%) followed by high responders (29.8%) and low responders (17.8%). The average FSH, HMG per day and number of days HMG required was found to be significant among the different responders. Further, retrieval rate and blastulation rate was found to be significant among the different responders. A positive correlation was found between AMH and number of oocytes retrieved and number of oocytes successfully fertilized and it was found to be significant. In addition, there was a significant inverse relationship between AMH levels and age.</span></p> <p><span>Conclusion</span></p> <p><span>The study outcome reveals that retrieval rate, maturation rate, fertilization rate, embryo utilization rate and blasturation rate were higher among the high responders as compared to low responders. Thus, proper increase in dosages of ovarian stimulation protocol is required among the low responders to achieve quality embryos. </span></p>
GERDAT013 Dataset for literature search linked to publication "Patient Preferences for Treatment Outcomes in Oncology with a Focus on the Older Patient—A Systematic Review"
<p>Dataset of the literature search belonging to the publication "Patient preferences for treatment outcomes in oncology with a focus on the older patient- a systematic review."</p>
Comparison-adjusted Funnell plots for the Primary outcomes: Treatment Failure, Endotracheal Ventilation and Moderate-Severe CLD
<p>Supplementary File #10 for Cochrane review entitled: "Non-invasive respiratory support in preterm infants as primary mode: a network meta-analysis"</p>
Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient
<p>Teriflunomide is a disease-modifying drug that has been approved for treatment of relapsing-remitting multiple sclerosis. Due to its teratogenic effect in animals, however, it is not recommended during pregnancy. For this reason, effective contraception must be used during its administration. When an unscheduled pregnancy occurs during therapy, patients must undergo a cholestyramine procedure for rapid flushing of the drug. We describe the case of a 35-year-old female patient suffering diagnosed with relapsing-remitting multiple sclerosis at the age of 20. The patient as a result of side effects of previous therapies started taking teriflunomide. Despite recommendations for the use of contraceptives, the patient became pregnant during drug therapy. Pregnancy occurred 12 months after initiating teriflunomide treatment. Therapy with teriflunomide was immediately suspended and cholestyramine was prescribed (8 g 3 times a day, for 11 days) to flush out any residual drug from the body. Despite an 8-week exposure to teriflumomide during gestation, the patient gave birth to healthy twin girls at 35<sup>th</sup> week. Controls carried out after birth did not reveal any malformation or genetic and chromosomal abnormality. At a 5-month pediatric specialist check both babies were healthy and growing regularly. This shows that even if there is evidence of teratogenic effects in animals, an 8-week exposure to teraflunomide >0.02 mg/L did not have effects on the newborn.</p>
Demographic data, disease characteristics, and laboratory findings for Association between polymorphisms within gene coding for tumor necrosis factor (TNF)-alpha with outcomes of treatment in sample of Iraqi patients with Ankylosing Spondylitis taking Etanercept
<p>Demographic data, disease characteristics, and laboratory findings for Association between polymorphisms within gene coding for tumor necrosis factor (TNF)-alpha with outcomes of treatment in sample of Iraqi patients with Ankylosing Spondylitis taking Etanercept</p>
Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial)
ClinicalTrials.gov study NCT05473689. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical and Radiological Outcomes of Subchondroplasty in the Treatment of Bone Marrow Edema of the Knee
ClinicalTrials.gov study NCT04905394. IPD Sharing: NO. Countries: 1. Publications: 1.
Standard Craniectomy Against Laparotomy for the Treatment of Traumatic Rise in Intracranial Pressure and the Effect on Long-term Outcome
ClinicalTrials.gov study NCT05115929. IPD Sharing: NO. Countries: 2. Publications: 1.
The Effect of Cryotherapy on the Outcome of Pulpotomy and Root Canal Treatment
ClinicalTrials.gov study NCT06183021. IPD Sharing: NO. Countries: 1. Publications: 3.
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm
ClinicalTrials.gov study NCT03515083. IPD Sharing: NO. Countries: 1. Publications: 10.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.